Division of Infection Control and Prevention, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan; Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Heart Lung. 2024 Sep-Oct;67:1-4. doi: 10.1016/j.hrtlng.2024.03.007. Epub 2024 Apr 2.
Few studies have investigated the prevalence of pathogens in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF), specifically, the interactions between respiratory pathogens and AE-IPF during the coronavirus disease 2019 (COVID-19) pandemic.
We aimed to analyze pathogens in patients with AE-IPF between September 2020 and December 2022.
This retrospective observational study was conducted at our hospital between September 2020 and December 2022. In patients with AE-IPF, pre-hospitalization polymerase chain reaction (PCR) tests for respiratory pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were performed using multiplex PCR or Smart Gene assay with nasopharyngeal swab specimens. Microbiological assays, including Gram staining, sputum cultures, blood cultures, and urinary antigen tests for Streptococcus pneumoniae and Legionella pneumophila, were also performed.
Forty-nine patients with AE-IPF were included. The median age was 75 years old and 42 (86 %) were male. Only one of the 49 patients (2 %) was positive for SARS-CoV-2. Two of 28 patients (7 %) were positive for human rhinovirus/enterovirus. No bacteria were detected in sputum culture, blood culture, or urinary antigen tests.
The detection frequency of SARS-CoV-2 infection in patients with AE-IPF was lower than that of human rhinovirus/enterovirus. Continuous analysis for the presence of pathogens is necessary for appropriate infection control because respiratory viruses may increase as the coronavirus pandemic subsides.
鲜有研究调查特发性肺纤维化急性加重（AE-IPF）患者中病原体的流行情况，特别是在 2019 冠状病毒病（COVID-19）大流行期间呼吸道病原体与 AE-IPF 之间的相互作用。
我们旨在分析 2020 年 9 月至 2022 年 12 月期间 AE-IPF 患者中的病原体。
这是一项在我院进行的回顾性观察性研究，时间为 2020 年 9 月至 2022 年 12 月。对 AE-IPF 患者，采用多重 PCR 或 Smart Gene 检测鼻咽拭子标本，进行呼吸道病原体（包括严重急性呼吸综合征冠状病毒 2（SARS-CoV-2））的住院前聚合酶链反应（PCR）检测。还进行了微生物学检测，包括革兰氏染色、痰培养、血培养和肺炎链球菌和嗜肺军团菌尿抗原检测。
纳入 49 例 AE-IPF 患者。中位年龄为 75 岁，42 例（86%）为男性。49 例患者中仅有 1 例（2%）为 SARS-CoV-2 阳性。28 例患者中有 2 例（7%）为人鼻病毒/肠道病毒阳性。痰培养、血培养或尿抗原检测均未检出细菌。
AE-IPF 患者中 SARS-CoV-2 感染的检出率低于人鼻病毒/肠道病毒。由于冠状病毒大流行消退，呼吸道病毒可能会增加，因此需要持续分析病原体的存在情况，以进行适当的感染控制。
